Adult acute lymphoblastic leukaemia

Renato Bassan, Gemma Gatta, Carlo Tondini, Roel Willemze

Research output: Contribution to journalArticle


Acute lymphoblastic leukaemia (ALL) in adults is a relatively rare neoplasm with a curability rate around 30% at 5 years. This consideration makes it imperative to dissect further the biological mechanisms of disease, in order to selectively implement an hitherto unsatisfactory success rate. The recognition of discrete ALL subtypes (some of which deserve specific therapeutic approaches, like T-lineage ALL (T-ALL) and mature B-lineage ALL (B-ALL)) is possible through an accurate combination of cytomorphology, immunophenotytpe and cytogenetic assays and has been a major result of clinical research studies conducted over the past 20 years. Two-three major prognostic groups are now easily identifiable, with a survival probability ranging from

Original languageEnglish
Pages (from-to)223-261
Number of pages39
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - Jun 2004


  • Acute lymphoblastic leukaemia (ALL)
  • B-lineage ALL
  • Clinical and laboratory issues
  • T-lineage ALL

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Adult acute lymphoblastic leukaemia'. Together they form a unique fingerprint.

  • Cite this